Streetbeat News

SLXN

Biomotion Sciences Ordinary Shares

Industry

Biotechnology

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Silexion Therapeutics Corp. (NASDAQ:SLXN) stock surged over 21% in pre-market trading following promising Phase 2 trial results for its pancreatic cancer treatment, LODER. The trial showed a 56% objective response rate, with a 67% rate in previously non-resectable tumors becoming resectable. The company is also developing SIL-204, targeting a broader range of KRAS mutations.

Portfolio Pulse from Vandana Singh

September 24, 2024 | 1:25 pm

Maison Solutions, Liberty Broadband, and Silexion Therapeutics are experiencing stock price movements due to significant company announcements. Maison Solutions reported a 163% increase in Q1 sales, Liberty Broadband submitted a counterproposal for a business combination, and Silexion Therapeutics announced new findings from a Phase 2 trial.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 12:07 pm

Silexion Therapeutics announced promising results from its Phase 2 trial of LODER for LAPC patients with KRAS mutations, showing a 56% ORR and 67% ORR in patients with resectable tumors.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 11:15 am

Dave & Buster's Entertainment, Inc. (NASDAQ:PLAY) shares surged 12.7% in pre-market trading after reporting better-than-expected earnings for Q2. The company posted earnings of $1.12 per share, surpassing the consensus estimate of 84 cents. However, sales slightly missed expectations at $557.1 million. Other stocks like CN Energy Group, FTC Solar, and Quhuo Limited also saw significant pre-market movements.

Portfolio Pulse from Avi Kapoor

September 11, 2024 | 9:16 am

Oracle shares surged by 8.8% in pre-market trading after reporting better-than-expected earnings and sales for Q1. Additionally, Oracle and Amazon's AWS launched Oracle Database@AWS, enhancing Oracle's cloud offerings. Other stocks like Silexion Therapeutics and Quoin Pharmaceuticals also saw significant pre-market movements.

Portfolio Pulse from Avi Kapoor

September 10, 2024 | 10:41 am

Recursion Pharmaceuticals shares fell 11.6% after announcing Phase 2 data for a treatment for Cerebral Cavernous Malformation. Nikola shares also dipped 10.4%. Meanwhile, Sify Technologies surged 103% after achieving a significant certification, and SPAR Group rose 65% following an acquisition agreement.

Portfolio Pulse from Avi Kapoor

September 03, 2024 | 5:41 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.